Newly Diagnosed Multiple Myeloma

CE / CME

What’s New in Newly Diagnosed Multiple Myeloma

Physician Assistants/Physician Associates: 1.00 AAPA Category 1 CME credit

Nurse Practitioners: 1.00 Nursing contact hours, includes 1.00 hour of pharmacotherapy credit

Released: May 16, 2024

Expiration: May 15, 2025

Charise Gleason
Charise Gleason, MSN, NP-C, AOCNP

Activity

Progress
1 2
Course Completed

References

  1. Kumar SK, Rajkumar V, Kyle RA, et al. Multiple myeloma. Nat Rev Dis Primers. 2017;3:17046.
  2. National Cancer Institute. Cancer stat facts: myeloma. seer.cancer.gov/statfacts/html/mulmy.html. Accessed May 2, 2024.
  3. Rajkumar SV, Dimopoulos MA, Palumbo A, et al. International Myeloma Working Group updated criteria for the diagnosis of multiple myeloma. Lancet Oncol. 2014;15:e538-548.
  4. Palumbo A, Avet-Loiseau H, Oliva S, et al. Revised International Staging System for multiple myeloma: A report from International Myeloma Working Group. J Clin Oncol. 2015;33:2863-2869.
  5. Usmani SZ, Rodriguez-Otero P, Bhutani M, et al. Defining and treating high-risk multiple myeloma. Leukemia. 2015;29:2119-2125.
  6. Soekojo CY, Chung TH, Furqan MS, et al. Genomic characterization of functional high-risk multiple myeloma patients. Blood Cancer J. 2022;12:24.
  7. Banerjee R, Cicero KI, Lee SS, et al. Definers and drivers of functional high-risk multiple myeloma: insights from genomic, transcriptomic, and immune profiling. Front Oncol. 2023;13:1240966.
  8. National Comprehsive Cancer Network. Clinical practice guidelines in oncology: multiple myeloma. Version 3.2024. nccn.org. Accessed May 2, 2024.
  9. D'Agostino M, Cairns DA, Lahuerta JJ, et al. Second revision of the International Staging System (R2-ISS) for overall survival in multiple myeloma: A European Myeloma Network (EMN) report within the HARMONY project. J Clin Oncol. 2022;40:3406-3418.
  10. Holstein SA. Current frontline treatment of multiple myeloma. Oncology (Williston Park). 2022;36:430-441.
  11. Voorhees PM, Sborov DW, Laubach J, et al. Addition of daratumumab to lenalidomide, bortezomib, and dexamethasone for transplantation-eligible patients with newly diagnosed multiple myeloma (GRIFFIN): final analysis of an open-label, randomised, phase 2 trial. Lancet Haematol. 2023;10:e825-e837.
  12. Sonneveld P, Dimopoulos MA, Boccadoro M, et al. Phase 3 randomized study of daratumumab + bortezomib, lenadlidomide, and dexamethasone (VRd) versus VRd alone in patients with newly diagnosed multiple myeloma who are eligible for autologous stem cell transplantation: primary results of the PERSEUS trial. Presented at: 65th American Society of Hematology Annual Meeting; December 9-12, 2023. Abstract LBA-1.
  13. Sonneveld P, Dimopoulos MA, Boccadoro M, et al. Daratumumab, bortezomib, lenalidomide, and dexamethasone for multiple myeloma. N Engl J Med. 2024;390:301-313.
  14. Joseph NS, DiCamillo SM, Roberts D, et al. Comparison of response and survival outcomes in newly diagnosed transplant-eligible multiple myeloma patients treated with RVD vs daratumumab and RVD. Presented at: 65th American Society of Hematology Annual Meeting; December 9-12, 2023. Abstract 647.
  15. Gay F, Roelozzfen W, Dimopoulos MA, et al. Results of the phase III randomized IsKia trial: isatuximab-carfilzomib-lenalidomide-dexamethasone vs carfilzomib-lenalidomide-dexamethasone as pre-transplant induction and post-transplant consolidation in newly diagnosed multiple myeloma patients. Presented at: 65th American Society of Hematology Annual Meeting; December 9-12, 2023. Abstract 4.
  16. Derudas D, Capraro F, Martinelli G, et al. How I manage frontline transplant-ineligible multiple myeloma. Hematol Rep. 2020;12:8956.
  17. Lazana I, Floro L, Christmas T, et al. Autologous stem cell transplantation for multiple myeloma patients with chronic kidney disease: a safe and effective option. Bone Marrow Transplant. 2022;57:959-965.
  18. Durie BGM, Hoering A, Sexton R, et al. Longer term follow-up of the randomized phase III trial SWOG S0777: bortezomib, lenalidomide and dexamethasone vs. lenalidomide and dexamethasone in patients (Pts) with previously untreated multiple myeloma without an intent for immediate autologous stem cell transplant (ASCT). Blood Cancer J. 2020;10:53.
  19. O’Donnell EK, Laubach JP, Yee AJ, et al. Updated results of a phase 2 study of modified lenalidomide, bortezomib, and dexamethasone (RVd-lite) in transplant-ineligible multiple myeloma. Presented at: 61st American Society of Hematology Annual Meeting; December 7-10, 2019. Abstract 3178.
  20. Kumar SK, Moreau P, Jacques N, et al. Daratumumab plus lenalidomide and dexamethasone (D-Rd) versus lenalidomide and dexamethasone (Rd) alone in transplant-ineligible patients with newly diagnosed multiple myeloma (NDMM): Updated analysis of the phase 3 MAIA study. Presented at: 64th American Society of Hematology Annual Meeting; December 10-13, 2022. Abstract 4559.
  21. Facon T, Lee JH, Moreau P, et al. Carfilzomib or bortezomib with melphalan-prednisone for transplant-ineligible patients with newly diagnosed multiple myeloma. Blood. 2019;133:1953-1963.
  22. Facon T, Venner CP, Bahlis NJ, et al. Oral ixazomib, lenalidomide, and dexamethasone for transplant-ineligible patients with newly diagnosed multiple myeloma. Blood. 2021;137:3616-3628.
  23. Hansen DK, Gautam S, Lafeuille M-H, et al. Comparison of time to next treatment or death between front-line daratumumab, lenalidomide, and dexamethasone (DRd) and bortezomib, lenalidomide, and dexamethasone (VRd) in transplant ineligible patients with multiple myeloma. Presented at: 64th American Society of Hematology Annual Meeting; December 10-13, 2022. Abstract 543.
  24. Ciltacabtagene autoleucel [prescribing information]. Horsham, PA: Jannsen Biotech, Inc; 2024.
  25. Idecabtagene autoleucel [prescribing information]. Summit, NJ: Bristol-Myers Squibb Company; 2024.
  26. Teclistamab [prescribing information]. Horsham, PA: Jannsen Biotech, Inc; 2024.
  27. Elranatamab [prescribing information]. New York, NY: Pfizer, Inc; 2023.
  28. Bortezomib [prescribing information]. Cambridge, MA: Millenium Pharmaceuticals; 2008.
  29. Raje NS, Yee AJ, Roodman GD. Advances in supportive care for multiple myeloma. J Natl Compr Canc Netw. 2014;12:502-511.
  30. Carfilzomib [prescribing information]. Thousand Oaks, CA: Onyx Pharmaceuticals; 2022.
  31. Lenalidomide [prescribing information]. Princeton, NJ: Bristol-Myers Squibb Company; 2023.
  32. Daratumumab [prescribing information]. Horsham, PA: Janssen Biotech, Inc; 2022.
  33. Isatuximab [prescribing information]. Bridgewater, NJ: Sanofi-Aventis; 2023.
  34. Quach H, Parmar G, Ocio E, et al. Subcutaneous (SC) isatuximab administration by an on-body delivery system (OBDS) in combination with pomalidomide-dexamethasone (Pd) in patients with relapsed/refractory multiple myeloma (RRMM): Interim phase 1b study results. Presented at: 58th Annual Meeting of the American Meeting of the American Society of Clinical Oncology; June 3-5, 2022. Abstract 8025.
  35. International Myeloma Foundation. Dexamethasone (steroid) side effects. myeloma.org/dexamethasone-side-effects. Accessed May 2, 2024.
  36. Brigle K, Pierre A, Finley-Oliver E, et al. Myelosuppression, bone disease, and acute renal failure: Evidence-based recommendations for oncologic emergencies. Clin J Oncol Nurs. 2017;21:60-76.
  37. Kambhampati S, Sheng Y, Huang CY, et al. Infectious complications in patients with relapsed refractory multiple myeloma after BCMA CAR T-cell therapy. Blood Adv. 2022;6:2045-2054.
  38. Noonan K, Rome S, Faiman B, et al. Heart and lung complications: Assessment and prevention of venous thromboembolism and cardiovascular disease in patients with multiple myeloma. Clin J Oncol Nurs. 2017;21:37-46.
  39. Fotiou D, Gavriatopoulou M, Terpos E. Multiple myeloma and thrombosis: Prophylaxis and risk prediction tools. Cancers (Basel). 2020;12.
  40. Bernstein ZS, Kim EB, Raje N. Bone disease in multiple myeloma: Biologic and clinical implications. Cells. 2022;11.